Upload
Featured Recent Articles Topics Login Upload

Search Results for ''

published presentations and documents on DocSlides.

Blinded Sample Size Re-estimation in a Phase III Study Investigating Progression Free Survival
Blinded Sample Size Re-estimation in a Phase III Study Investigating Progression Free Survival
by naomi
David Morgan (King’s College, London / Consultan...
End-points utilized in
End-points utilized in
by marina-yarberry
End-points utilized in breast cancer clinical ...
End-points utilized in breast cancer
End-points utilized in breast cancer
by evelyn
clinical . trials - Discussion. Novartis Oncology...
Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone in Relapsed or Ref
Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone in Relapsed or Ref
by willow
Meletios Dimopoulos,. 1. Hang Quach,. 2. Maria-V...
YIR On Demand Lung Benjamin Levy, MD 
YIR On Demand Lung Benjamin Levy, MD 
by jovita
Assistant Professor. Johns Hopkins School of Medic...
ESMO 2021 (Virtual) Congress Report
ESMO 2021 (Virtual) Congress Report
by SnuggleBug
Lung and gastrointestinal cancers. Slide numbers. ...
Jointly provided by & This activity is supported by educations grants from Novartis Pharmaceuticals Corporation, Pfizer, and Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com
Jointly provided by & This activity is supported by educations grants from Novartis Pharmaceuticals Corporation, Pfizer, and Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com
by olivia-moreira
Jointly provided by ...
Managing Advanced Renal Cell
Managing Advanced Renal Cell
by debby-jeon
Carcinoma: Balancing . Efficacy with Quality of L...
Blinded Sample Size Re-estimation in a Phase III Study Inve
Blinded Sample Size Re-estimation in a Phase III Study Inve
by luanne-stotts
David Morgan (King’s College, London / Consulta...
Indolent Non-Hodgkin L
Indolent Non-Hodgkin L
by danika-pritchard
ymphoma. Sobia Ozair. March 8, 2017. MD Anderson ...
Update on transplant-ineligible patients:
Update on transplant-ineligible patients:
by trish-goza
Which . regimens are best?. Suzanne Lentzsch MD, ...
End-Points and Rationale for Phase III Trials in HCC: Adjuvant, Intermediate, and Advanced HCC
End-Points and Rationale for Phase III Trials in HCC: Adjuvant, Intermediate, and Advanced HCC
by maniakti
Richard S. Finn, MD. Professor of Clinical Medicin...
Analysis of Sustained MRD-Negativity and Progression-Free Survival of Isa-KRd in High-Risk Newly Diagnosed Multiple Myeloma Additional Data From Planned Interim Analysis of the GMMG-CONCEPT Trial
Analysis of Sustained MRD-Negativity and Progression-Free Survival of Isa-KRd in High-Risk Newly Diagnosed Multiple Myeloma Additional Data From Planned Interim Analysis of the GMMG-CONCEPT Trial
by ayaan
Progression-Free Survival of Isa-. KRd. in High-R...
Department of GI Medical Oncology
Department of GI Medical Oncology
by danika-pritchard
Does . the New EPOC trial . eliminate. . Anti. -...
Have the OPTIMOX-2, CAIRO-3, COIN, DREAM and other recent t
Have the OPTIMOX-2, CAIRO-3, COIN, DREAM and other recent t
by sherrill-nordquist
Yes . Deborah . Schrag. , MD, MPH. No. John L. Ma...
Second line
Second line
by alida-meadow
treatments. in WT . pts. : . which. . opportuni...
Jon Trent, MD, PhD Professor of Medicine
Jon Trent, MD, PhD Professor of Medicine
by jane-oiler
Sarcoma . Medical Oncology. The University of . M...
Emanuele Zucca, MD Oncology Institute of Southern Switzerland (IOSI)
Emanuele Zucca, MD Oncology Institute of Southern Switzerland (IOSI)
by ellena-manuel
Swiss Group for Clinical Cancer Research (SAKK). ...
The Impending D eath of Cancer: A Herculean Task Emerging Therapies 2016
The Impending D eath of Cancer: A Herculean Task Emerging Therapies 2016
by phoebe-click
The Impending D eath of Cancer: A Herculean Task...
Overall Survival Benefit of
Overall Survival Benefit of
by tatyana-admore
Obinutuzumab. Over Rituximab when Combined with ...
NEw developments IN gynecological Oncology
NEw developments IN gynecological Oncology
by cheryl-pisano
highlights from the. EUROPEAN . society . of med...
Romidepsin in Association with CHOP in Patients with Peripheral T
Romidepsin in Association with CHOP in Patients with Peripheral T
by accompanypepsi
-Cell . Lymphoma: Final Results of the Phase . Ib....
by billiontins
2018;36(8):773-9.. Nivolumab Monotherapy (Cohort 1...
Molecular Lessons Learnt from Clinical Trials in the Last Decade
Molecular Lessons Learnt from Clinical Trials in the Last Decade
by altigan
Andrew X. Zhu, MD, PhD. Harvard Medical School. Ma...
Advances in Systemic Amyloidosis:
Advances in Systemic Amyloidosis:
by morton
A Spotlight on New Disease-Modifying . Therapies A...
Updates on T-cell lymphoma
Updates on T-cell lymphoma
by grace3
Dr. Stefan K. Barta. University of Pennsylvania, U...
The Impending D eath of Cancer:
The Impending D eath of Cancer:
by elina
A Herculean Task. Emerging Therapies 2016. Ruemu E...
First Prospective Data on Minimal Residual Disease (MRD) Outcomes After Fixed-Duration Ibrutinib P
First Prospective Data on Minimal Residual Disease (MRD) Outcomes After Fixed-Duration Ibrutinib P
by mia
Ibr+Ven. ) Versus Chlorambucil Plus Obinutuzumab (...
Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor
Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor
by byrne
Overall survival and updated progression-free surv...
GI CONNECT MEETING SUMMARY
GI CONNECT MEETING SUMMARY
by hanah
upper . gi. cancer HIGHLIGHTS . FROM ESMO 2022. D...
Meeting summary ASCO GU 2020,
Meeting summary ASCO GU 2020,
by patricia
San Francisco. , USA. Assoc. . Prof. . Shilpa Gupt...
INTRODUCTION RESULTS
INTRODUCTION RESULTS
by arjun383
Mason Alford, MSc. a. , . Candace J. Grisham, MS. ...